Future treatments for AD can generally be divided into 2 primary directions [26]: one involves targeting and clearing biochemical markers, such as neurofibrillary tangles [composed of phosphorylated tau (p-tau)] and amyloid plaques (Aβ), to prevent or slow neurodegeneration [27]; the other aims at enhancing neuronal connectivity to improve cognitive function [28]. The gene discussed is MAPT; the disease is Alzheimer disease.